KRAS and lung carcinoma: As newer classes of targeted therapies are developed, such as KRAS, P53, PI3K and EGFR inhibitors53, and more anti-lung cancer drugs are developed to specific genetic targets, it is important to develop immunocompetent mouse models capable of responding to treatments.